• Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Governance Reports & Policies

Governance Documents & Policies

UNGC Membership - Jan 2023
Business Responsibility Policy
Syngene Human Rights Policy
Policy Document on Material Subsidiaries
Policy on Director’s Appointment and Remuneration
Environment, Occupational Health, Safety and Sustainability Policy
Policy for Preservation of Documents
Policy for Determining Materiality for Disclosures
Syngene - Memorandum of Association & Articles of Association
Code of Conduct for Prevention of Insider Trading
Corporate Social Responsibility Policy
Integrity and Whistle-blower Policy
Dividend Distribution Policy
Policy document on Board Diversity
Policy on Related Party Transactions
Familiarisation Policy and Details of Familiarisation Programme
Letter of Appointment for Independent Directors
Code of Conduct and Duties for Independent Directors
Code of Ethics and Business Conduct
Supplier code of conduct

Corporate Governance Reports

Q4 Corporate Governance Report March 31, 2023
Q3 Corporate Governance Report December 31, 2022
Q2 Corporate Governance Report September 30, 2022
Q1 Corporate Governance Report June 30, 2022

Syngene has engaged various vendors for delivery of goods and services. Some of such vendors qualify as micro, small and medium enterprises (“MSME”) under the Micro, Small and Medium Enterprises Development Act, 2006 (“Act”). To ensure timely payment and resolution to queries for outstanding unreconciled balances, vendors are requested to reach out to Accounts Helpdesk- Accounts.Helpdesk@Syngeneintl.com

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details